Literature DB >> 8701997

P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain.

L S Higgins1, G M Murphy, L S Forno, R Catalano, B Cordell.   

Abstract

The presence of beta-amyloid in brain tissue is characteristic of Alzheimer's disease (AD). A naturally occurring derivative of the beta-amyloid peptide, p3, possesses all of the structural determinants required for fibril assembly and neurotoxicity. p3-specific antibodies were used to examine the distribution of this peptide in brain. p3 reactivity was absent or sparse in aged non-AD brains but was prevalent in selected areas of AD brain in diffuse deposits and in a subset of dystrophic neurites. p3-reactive dystrophic neurites were found both independent in the neuropil and associated with plaques. Little or no reactivity was observed to amyloid cores in classical plaques or to amyloid in the cerebral vasculature. The exclusive appearance of p3 reactivity in AD brain plus the selective localization of p3 reactivity to abnormal structures in the temporal lobe limbic system suggests that p3 may be a contributing factor to AD pathology.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8701997      PMCID: PMC1865300     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  59 in total

1.  Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides.

Authors:  C Hilbich; B Kisters-Woike; J Reed; C L Masters; K Beyreuther
Journal:  J Mol Biol       Date:  1992-11-20       Impact factor: 5.469

Review 2.  In pursuit of the molecular structure of amyloid plaque: new technology provides unexpected and critical information.

Authors:  P T Lansbury
Journal:  Biochemistry       Date:  1992-08-04       Impact factor: 3.162

3.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

4.  Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra.

Authors:  C J Barrow; A Yasuda; P T Kenny; M G Zagorski
Journal:  J Mol Biol       Date:  1992-06-20       Impact factor: 5.469

5.  Amyloid beta-peptide is produced by cultured cells during normal metabolism.

Authors:  C Haass; M G Schlossmacher; A Y Hung; C Vigo-Pelfrey; A Mellon; B L Ostaszewski; I Lieberburg; E H Koo; D Schenk; D B Teplow
Journal:  Nature       Date:  1992-09-24       Impact factor: 49.962

6.  Alzheimer's disease. Beta-amyloid precursor protein expression in the nucleus basalis of Meynert.

Authors:  G M Murphy; B D Greenberg; W G Ellis; L S Forno; S M Salamat; P A Gonzalez-DeWhitt; D E Lowery; J R Tinklenberg; L F Eng
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

7.  Activation of microglial cells by beta-amyloid protein and interferon-gamma.

Authors:  L Meda; M A Cassatella; G I Szendrei; L Otvos; P Baron; M Villalba; D Ferrari; F Rossi
Journal:  Nature       Date:  1995-04-13       Impact factor: 49.962

8.  Mass spectrometry of purified amyloid beta protein in Alzheimer's disease.

Authors:  H Mori; K Takio; M Ogawara; D J Selkoe
Journal:  J Biol Chem       Date:  1992-08-25       Impact factor: 5.157

Review 9.  Methodological variables in the assessment of beta amyloid neurotoxicity.

Authors:  J Busciglio; A Lorenzo; B A Yankner
Journal:  Neurobiol Aging       Date:  1992 Sep-Oct       Impact factor: 4.673

10.  Production of the Alzheimer amyloid beta protein by normal proteolytic processing.

Authors:  M Shoji; T E Golde; J Ghiso; T T Cheung; S Estus; L M Shaffer; X D Cai; D M McKay; R Tintner; B Frangione
Journal:  Science       Date:  1992-10-02       Impact factor: 47.728

View more
  17 in total

1.  Microglia in Alzheimer's disease and transgenic models. How close the fit?

Authors:  D W Dickson
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  β-Barrel topology of Alzheimer's β-amyloid ion channels.

Authors:  Hyunbum Jang; Fernando Teran Arce; Srinivasan Ramachandran; Ricardo Capone; Ratnesh Lal; Ruth Nussinov
Journal:  J Mol Biol       Date:  2010-10-21       Impact factor: 5.469

Review 3.  Disordered amyloidogenic peptides may insert into the membrane and assemble into common cyclic structural motifs.

Authors:  Hyunbum Jang; Fernando Teran Arce; Srinivasan Ramachandran; Bruce L Kagan; Ratnesh Lal; Ruth Nussinov
Journal:  Chem Soc Rev       Date:  2014-10-07       Impact factor: 54.564

4.  Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis.

Authors:  R Lyle Patton; Walter M Kalback; Chera L Esh; Tyler A Kokjohn; Gregory D Van Vickle; Dean C Luehrs; Yu-Min Kuo; John Lopez; Daniel Brune; Isidro Ferrer; Eliezer Masliah; Amanda J Newel; Thomas G Beach; Eduardo M Castaño; Alex E Roher
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

Review 5.  APP/Aβ structural diversity and Alzheimer's disease pathogenesis.

Authors:  Alex E Roher; Tyler A Kokjohn; Steven G Clarke; Michael R Sierks; Chera L Maarouf; Geidy E Serrano; Marwan S Sabbagh; Thomas G Beach
Journal:  Neurochem Int       Date:  2017-08-12       Impact factor: 3.921

Review 6.  Alzheimer disease.

Authors:  Rudy J Castellani; Raj K Rolston; Mark A Smith
Journal:  Dis Mon       Date:  2010-09       Impact factor: 3.800

7.  Molecular interactions of Alzheimer amyloid-β oligomers with neutral and negatively charged lipid bilayers.

Authors:  Xiang Yu; Qiuming Wang; Qingfen Pan; Feimeng Zhou; Jie Zheng
Journal:  Phys Chem Chem Phys       Date:  2013-03-14       Impact factor: 3.676

8.  A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model.

Authors:  Rolf Postina; Anja Schroeder; Ilse Dewachter; Juergen Bohl; Ulrich Schmitt; Elzbieta Kojro; Claudia Prinzen; Kristina Endres; Christoph Hiemke; Manfred Blessing; Pascaline Flamez; Antoine Dequenne; Emile Godaux; Fred van Leuven; Falk Fahrenholz
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

Review 9.  Is the p3 Peptide (Aβ17-40, Aβ17-42) Relevant to the Pathology of Alzheimer's Disease?1.

Authors:  Ariel J Kuhn; Jevgenij Raskatov
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

10.  Polymorphism of Alzheimer's Abeta17-42 (p3) oligomers: the importance of the turn location and its conformation.

Authors:  Yifat Miller; Buyong Ma; Ruth Nussinov
Journal:  Biophys J       Date:  2009-08-19       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.